Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

```
                organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:42:11 ON 24 JUL 2008

=> FIL REGISTRY
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:42:25 ON 24 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 JUL 2008  HIGHEST RN 1035393-16-8
DICTIONARY FILE UPDATES:  22 JUL 2008  HIGHEST RN 1035393-16-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E "CHLORAMBUCIL"/CN 25
E1            1     CHLORAMBIN/CN
E2            1     CHLORAMBON/CN
E3            1 --> CHLORAMBUCIL/CN
E4            1     CHLORAMBUCIL 2-(TRIPHENYLMETHOXY)ETHYL ESTER/CN
E5            1     CHLORAMBUCIL ACID CHLORIDE/CN
E6            1     CHLORAMBUCIL HEXYL ESTER/CN
```

```
E7            1     CHLORAMBUCIL ISOPROPYL ESTER/CN
E8            1     CHLORAMBUCIL METHYL ESTER/CN
E9            1     CHLORAMBUCIL N-HYDROXYSUCCINIMIDE ESTER/CN
E10           1     CHLORAMBUCIL N-OXIDE/CN
E11           1     CHLORAMBUCIL OCTYL ESTER/CN
E12           1     CHLORAMBUCIL PHENYLETHYL ESTER/CN
E13           1     CHLORAMBUCIL PHENYLMETHYL ESTER/CN
E14           1     CHLORAMBUCIL POTASSIUM SALT/CN
E15           1     CHLORAMBUCIL PROPYL ESTER/CN
E16           1     CHLORAMBUCIL SILVER SALT/CN
E17           1     CHLORAMBUCIL SODIUM SALT/CN
E18           1     CHLORAMBUCIL TERT-BUTYL ESTER/CN
E19           1     CHLORAMBUCIL-B,B-D2/CN
E20           1     CHLORAMBUCIL-ARG-VAL-TYR-ILE-HIS-PRO-PHE/CN
E21           1     CHLORAMBUCIL-ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE/CN
E22           1     CHLORAMBUCIL-BUSULFAN MIXTURE/CN
E23           1     CHLORAMBUCIL-HIS-PRO-PHE/CN
E24           1     CHLORAMBUCIL-ILE-HIS-PRO-PHE/CN
E25           1     CHLORAMBUCIL-TETRAZOLIUM VIOLET MIXTURE/CN

=> S E3
L1            1 CHLORAMBUCIL/CN

=> E "IMATINIB"/CN 25
E1            1     IMASORB A 700/CN
E2            1     IMASORB G 700/CN
E3            1 --> IMATINIB/CN
E4            1     IMATINIB MESILATE/CN
E5            1     IMATINIB MESYLATE/CN
E6            1     IMAVATE/CN
E7            1     IMAVEROL/CN
E8            1     IMAWOOD/CN
E9            1     IMAXILIN/CN
E10           1     IMAZABENZ/CN
E11           1     IMAZALIL/CN
E12           1     IMAZALIL HYDROCHLORIDE/CN
E13           1     IMAZALIL NITRATE/CN
E14           1     IMAZALIL PHOSPHATE/CN
E15           1     IMAZALIL SULFATE/CN
E16           1     IMAZALIL-BOSCALID MIXT./CN
E17           1     IMAZALIL-CARPROPAMID MIXT./CN
E18           1     IMAZALIL-CHLORFENAPYR MIXT./CN
E19           1     IMAZALIL-EPOXICONAZOLE MIXT./CN
E20           1     IMAZALIL-IKI 220 MIXT./CN
E21           1     IMAZALIL-PIPERONYL BUTOXIDE MIXT./CN
E22           1     IMAZALIL-TEBUCONAZOLE MIXT./CN
E23           1     IMAZALIL-THIABENDAZOLE MIXT./CN
E24           1     IMAZALIL-TOLYLFLUANID MIXT./CN
E25           1     IMAZAMETH/CN

=> S E3
L2            1 IMATINIB/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   305-03-3  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]- (8CI)
OTHER NAMES:
```

CN γ-[p-Bis(2-chloroethyl)aminophenyl]butyric acid
CN γ-[p-Di(2-chloroethyl)aminophenyl]butyric acid
CN 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid
CN 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid
CN Ambochlorin
CN Amboclorin
CN CB 1348
CN Chlorambucil
CN Chloraminophene
CN Chlorbutin
CN Chlorobutine
CN Ecloril
CN Leukeran
CN Leukeran Tablets
CN Linfolizin
CN Linfolysin
CN Lympholysin
CN NCI 3088
CN NSC 3088
MF C14 H19 Cl2 N O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
      (*File contains numerically searchable property data)
    Other Sources: EINECS**, WHO
      (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2670 REFERENCES IN FILE CA (1907 TO DATE)
 187 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2682 REFERENCES IN FILE CAPLUS (1907 TO DATE)
  34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 152459-95-5 REGISTRY
ED Entered STN: 25 Jan 1994
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
CN CGP 57148
CN Imatinib
MF C29 H31 N7 O

CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1457 REFERENCES IN FILE CA (1907 TO DATE)
25 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1478 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.22	15.43

FILE 'MEDLINE' ENTERED AT 09:43:38 ON 24 JUL 2008

FILE 'CAPLUS' ENTERED AT 09:43:38 ON 24 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:43:38 ON 24 JUL 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 09:43:38 ON 24 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and l2
L3 134 L1 AND L2

=> s l3 and combination
L4 99 L3 AND COMBINATION

=> s l4 and CLL
L5 15 L4 AND CLL

=> s l4 not py>2002
L6 0 L4 NOT PY>2002

=> s l4 and py<2003
2 FILES SEARCHED...
L7 0 L4 AND PY<2003

=> s l4 and py<2004
2 FILES SEARCHED...

```
L8           1 L4 AND PY<2004

=> d 18

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2003:892800  CAPLUS
DN   139:395950
TI   Preparation of substituted pyrazines as protein kinase modulators
IN   Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang,
     Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen,
     Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.;
     Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp,
     Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa
     Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann,
     Lary Wayne; Takeuchi, Craig Stacy
PA   Exelixis, Inc., USA
SO   PCT Int. Appl., 468 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2003093297       A2     20031113    WO 2003-US13869        20030502 <--
     WO 2003093297       A3     20040701
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2484209           A1     20031113    CA 2003-2484209        20030502 <--
     AU 2003234464        A1     20031117    AU 2003-234464         20030502 <--
     EP 1501514           A2     20050202    EP 2003-728690         20030502
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005530760        T      20051013    JP 2004-501436         20030502
     US 20060211709       A1     20060921    US 2005-513081         20050727
PRAI US 2002-377933P      P      20020503
     WO 2003-US13869      W      20030502
OS   MARPAT 139:395950


=> d l5 1-15 ibib, abs

L5   ANSWER 1 OF 15     MEDLINE on STN
ACCESSION NUMBER:   2004091574     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 14712290
TITLE:              Imatinib sensitizes CLL lymphocytes to
                    chlorambucil.
AUTHOR:             Aloyz R; Grzywacz K; Xu Z-Y; Loignon M; Alaoui-Jamali M A;
                    Panasci L
CORPORATE SOURCE:   Lady Davis Institute for Medical Research, Sir Mortimer B
                    Davis - Jewish General Hospital, Montreal, Quebec, Canada.
SOURCE:             Leukemia : official journal of the Leukemia Society of
                    America, Leukemia Research Fund, U.K, (2004 Mar) Vol. 18,
                    No. 3, pp. 409-14.
                    Journal code: 8704895. ISSN: 0887-6924.
```

PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 25 Feb 2004
Last Updated on STN: 25 Mar 2004
Entered Medline: 24 Mar 2004

AB The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib (</=10 microM), which are achievable in patients with minimal toxicity. Moreover, the combination of both drugs results in increased apoptosis in CLL cell lines. These results suggest that imatinib should be useful in improving the therapeutic index of CLB in CLL. The mechanism of action appears to involve imatinib inhibition of c-abl kinase activity with an associated decrease in CLB-induced Rad51 phosphorylation and CLB-induced Rad51 nuclear foci, suggesting that imatinib decreases Rad51-related DNA repair of CLB-induced DNA lesions. Altogether, our results suggest that imatinib is a promising adjuvant therapy to CLB treatment of CLL.

L5 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:283298 CAPLUS
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273910	A1	20050331	AU 2004-273910	20040916
CA 2538570	A1	20050331	CA 2004-2538570	20040916
EP 1670477	A2	20060621	EP 2004-788798	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004014568	A	20061107	BR 2004-14568		20040916
CN 1878556	A	20061213	CN 2004-80033294		20040916
JP 2007505914	T	20070315	JP 2006-527024		20040916
MX 2006PA03066	A	20060620	MX 2006-PA3066		20060317
NO 2006001325	A	20060606	NO 2006-1325		20060323
KR 2007012618	A	20070126	KR 2006-707244		20060414
PRIORITY APPLN. INFO.:			US 2003-504310P	P	20030918
			WO 2004-US30368	W	20040916

OTHER SOURCE(S): MARPAT 142:349042

AB The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.

L5 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:149921 CAPLUS
DOCUMENT NUMBER: 141:253838
TITLE: Imatinib sensitizes CLL lymphocytes to chlorambucil
AUTHOR(S): Aloyz, R.; Grzywacz, K.; Xu, Z-Y.; Loignon, M.; Alaoui-Jamali, M. A.; Panasci, L.
CORPORATE SOURCE: Lady Davis Institute for Medical Research, Sir Mortimer B Davis - Jewish General Hospital, Montreal, QC, Can.
SOURCE: Leukemia (2004), 18(3), 409-414
CODEN: LEUKED; ISSN: 0887-6924
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, resp., to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concns. of imatinib (≤10 μM), which are achievable in patients with minimal toxicity. Moreover, the combination of both drugs results in increased apoptosis in CLL cell lines. These results suggest that imatinib should be useful in improving the therapeutic index of CLB in CLL. The mechanism of action appears to involve imatinib inhibition of c-abl kinase activity with an associated decrease in CLB-induced Rad51 phosphorylation and CLB-induced Rad51 nuclear foci, suggesting that imatinib decreases Rad51-related DNA repair of CLB-induced DNA lesions. Altogether, our results suggest that imatinib is a promising adjuvant therapy to CLB treatment of CLL.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:135102 USPATFULL
TITLE: Treatment of hyperproliferative diseases with anthraquinones
INVENTOR(S): Cleland, Jeffrey L., San Carlos, CA, UNITED STATES
Wong, Alvin, San Francisco, CA, UNITED STATES
Lalani, Alshad S., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Novacea, Inc. (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 20070117784 A1 20070524
APPLICATION INFO.: US 2006-520034 A1 20060913 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2006-US7452, filed on 3 Mar 2006, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-658371P	20050304 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 1756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to anthraquinone compounds having activity for treating hyperproliferative disorders. Further, the invention relates to methods of using the compounds, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2006:302296 USPATFULL
TITLE: Compositions and methods for treating cancer
INVENTOR(S): Matteucci, Mark, Portola Valley, CA, UNITED STATES
Rao, Photon, Foster City, CA, UNITED STATES
Duan, Jian-Xin, South San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Threshold Pharmaceuticals, Inc., Redwood City, CA, UNITED STATES, 94063 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060258656	A1	20061116	
APPLICATION INFO.:	US 2004-549545	A1	20040329	(10)
	WO 2004-US9667		20040329	
			20060526	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458845P	20030328 (60)
	US 2003-465281P	20030421 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 3572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2006:144668 USPATFULL
TITLE: Combination of a nitrogen mustard analogue

and imatinib for the treatment of chronic lymphocytic leukemia

INVENTOR(S): Panasci, Lawrence Carl, Quebec, CANADA
Aloyz, Raquel Silvia, Montreal, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060122186	A1	20060608	
APPLICATION INFO.:	US 2003-534573	A1	20031110	(10)
	WO 2003-IB5454		20031110	
			20051102	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60425481	20021112

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula ##STR1## or a pharmaceutically acceptable salt thereof, the invention pertains to the use of said combination for the treatment chronic lymphocytic leukemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2006:68089 USPATFULL
TITLE: Combinations for the treatment of diseases involving cell proliferation
INVENTOR(S): Munzert, Gerd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Steegmaier, Martin, Wien, AUSTRIA
Baum, Anke, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060058311	A1	20060316	
APPLICATION INFO.:	US 2005-189540	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-19361	20040814
	EP 2004-19448	20040817

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 3176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) ##STR1## wherein the groups L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2006:15843 USPATFULL
TITLE: Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
INVENTOR(S): Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PATENT ASSIGNEE(S): Aurelium BioPharma Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060014225	A1	20060119
APPLICATION INFO.:	US 2005-173672	A1	20050701 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-736889, filed on 15 Dec 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-433480P	20021213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 126
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 5552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:171786 USPATFULL
TITLE: IAP nucleobase oligomers and oligomeric complexes and uses thereof
INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050148535	A1	20050707
APPLICATION INFO.:	US 2004-975974	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516192P	20031030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	3022	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2005:138567 USPATFULL		
TITLE:	Methods and reagents for the treatment of proliferative diseases		
INVENTOR(S):	LaCasse, Eric, Ottawa, CANADA McManus, Daniel, Ottawa, CANADA Durkin, Jon P., Montreal, CANADA		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050119217	A1	20050602
APPLICATION INFO.:	US 2004-975790	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516263P	20031030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	5896	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features methods, compositions, and kits for treating a patient having a proliferative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2005:30800 USPATFULL
TITLE:	Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
INVENTOR(S):	Georges, Elias, Laval, CANADA Serfass, Lucile, Montreal, CANADA Bonneau, Anne-Marie, Laval, CANADA Dallaire, Frederic, Montreal, CANADA

PATENT ASSIGNEE(S): Aurelium BioPharma, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050026231	A1	20050203
	US 7358042	B2	20080415
APPLICATION INFO.:	US 2004-801988	A1	20040315 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455005P	20030314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:10985 USPATFULL
TITLE: Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
INVENTOR(S): Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PATENT ASSIGNEE(S): Aurelium BioPharma, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050009119	A1	20050113
APPLICATION INFO.:	US 2003-737712	A1	20031215 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-433351P	20021213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 108
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 5859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) protein on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin protein on the surface of a normal cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:334230 USPATFULL
TITLE: Anti-IGF-I receptor antibody
INVENTOR(S): Singh, Rajeeva, Cambridge, MA, UNITED STATES
Tavares, Daniel J., Natick, MA, UNITED STATES
Dagdigian, Nancy E., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): IMMUNOGEN INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040265307	A1	20041230
APPLICATION INFO.:	US 2003-729441	A1	20031208 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-170390, filed on 14 Jun 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 3446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:327292 USPATFULL
TITLE: Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
INVENTOR(S): Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PATENT ASSIGNEE(S): Aurelium BioPharma Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040259112	A1	20041223
APPLICATION INFO.:	US 2003-736889	A1	20031215 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-433480P	20021213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE

```
                          STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:         108
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       21 Drawing Page(s)
LINE COUNT:               5789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Disclosed are methods for detecting multidrug resistance in neoplastic
       or damaged cells or multidrug resistant (MDR) neoplastic or damaged
       cells by detecting an increase in the cell surface expression of
       vimentin protein in such cells as compared to the level of cell surface
       expression of vimentin protein in a normal cell or a non-MDR neoplastic
       cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 15 OF 15  USPATFULL on STN
ACCESSION NUMBER:         2004:239705  USPATFULL
TITLE:                    HSC70 directed diagnostics and therapeutics for
                          multidrug resistant neoplastic disease
INVENTOR(S):              Georges, Elias, Laval, CANADA
                          Serfass, Lucile, Montreal, CANADA
                          Bonneau, Anne-Marie, Laval, CANADA
                          Dallaire, Frederic, Montreal, CANADA
PATENT ASSIGNEE(S):       Aurelium BioPharma, Inc. (non-U.S. corporation)

                               NUMBER         KIND    DATE
                          --------------- ------ --------
PATENT INFORMATION:       US 20040185511     A1   20040923
                          US 7226748         B2   20070605
APPLICATION INFO.:        US 2003-737350     A1   20031215  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2003-438012P    20030103 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE
                          STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:         108
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       30 Drawing Page(s)
LINE COUNT:               5612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Disclosed are methods for detecting neoplastic or damaged cells and for
       detecting multidrug resistance in neoplastic or damaged cells by
       detecting an increase in the cell surface expression of a heat shock
       cognate (HSC70) protein 70 on the surface of such a multidrug resistant
       neoplastic or damaged cells as compared to the level of expression of
       the HSC70 protein on the surface of a normal cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 09:42:11 ON 24 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 09:42:25 ON 24 JUL 2008
               E "CHLORAMBUCIL"/CN 25
L1             1 S E3
               E "IMATINIB"/CN 25
L2             1 S E3
```

```
     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 09:43:38 ON 24 JUL
     2008
L3           134 S L1 AND L2
L4            99 S L3 AND COMBINATION
L5            15 S L4 AND CLL
L6             0 S L4 NOT PY>2002
L7             0 S L4 AND PY<2003
L8             1 S L4 AND PY<2004

=> file medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     57.19      72.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -1.60      -1.60

FILE 'MEDLINE' ENTERED AT 09:48:35 ON 24 JUL 2008

 FILE LAST UPDATED: 23 Jul 2008 (20080723/UP).  FILE COVERS 1949 TO DATE.

  MEDLINE has been updated with the National Library of Medicine's
  revised 2008 MeSH terms.  See HELP RLOAD for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

  See HELP RANGE before carrying out any RANGE search.

=> s l1 and l2
          3217 L1
          3606 L2
L9           3 L1 AND L2

=> d l9 1-3 ibib abs

L9   ANSWER 1 OF 3     MEDLINE on STN
ACCESSION NUMBER:   2005125321     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 15755509
TITLE:              Cytokinetics and mechanism of action of AKO4: a novel
                    nitrogen mustard targeted to bcr-abl.
AUTHOR:             Katsoulas Athanasia; Rachid Zakaria; Brahimi Fouad; McNamee
                    James; Jean-Claude Bertrand J
CORPORATE SOURCE:   Cancer Drug Research Laboratory, Department of Medicine,
                    Division of Medical Oncology, McGill University Health
                    Center/Royal Victoria Hospital, 687 Pine Ave. West, M7.19,
                    Montreal, Que., Canada H3A 1A1.
SOURCE:             Leukemia research, (2005 May) Vol. 29, No. 5, pp. 565-72.
                    Electronic Publication: 2005-01-26.
                    Journal code: 7706787. ISSN: 0145-2126.
PUB. COUNTRY:       England: United Kingdom
DOCUMENT TYPE:      (COMPARATIVE STUDY)
                    Journal; Article; (JOURNAL ARTICLE)
                    (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        200506
ENTRY DATE:         Entered STN: 10 Mar 2005
                    Last Updated on STN: 9 Jun 2005
                    Entered Medline: 8 Jun 2005
```

AB The "combi-targeting" concept seeks to design molecules to not only block tyrosine kinase (TK) activity but also to induce DNA damage. Here we design AK04, a molecule that combines the pharmacophore chlorambucil with that of STI-571 (Gleevec). The results showed that although a less potent abl TK inhibitor than STI571, AK04 was capable of significantly blocking bcr-abl phosphorylation not only in a purified abl assay but also in the bcr-abl+ K562 cells. In contrast to STI571 and like chlorambucil, it induced a dose-dependent increase in DNA damage in these cells. More importantly, AK04 was 12-32-fold more potent than chlorambucil in all bcr-abl+ cells of our cell panel. In the isogenic human megakaryocytic Mo7e and Mo7/bcr-abl cells, AK04 selectively killed the bcr-abl transfectants. Flow cytometry revealed that despite being a five-fold less potent inhibitor of bcr-abl than STI-571, it induced a significant dose-dependent increase in levels of cell death by apoptosis in KU812 cells 24 h post-treatment. Under these conditions, chlorambucil did not induce any significant level of apoptosis. These results suggest that AK04 is a nitrogen mustard with binary bcr-abl/DNA targeting effects, a property that may account for its superior potency when compared with the classical mustard chlorambucil.

L9 ANSWER 2 OF 3 MEDLINE on STN
ACCESSION NUMBER: 2004091574 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14712290
TITLE: Imatinib sensitizes CLL lymphocytes to chlorambucil.
AUTHOR: Aloyz R; Grzywacz K; Xu Z-Y; Loignon M; Alaoui-Jamali M A; Panasci L
CORPORATE SOURCE: Lady Davis Institute for Medical Research, Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada.
SOURCE: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, (2004 Mar) Vol. 18, No. 3, pp. 409-14.
Journal code: 8704895. ISSN: 0887-6924.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 25 Feb 2004
Last Updated on STN: 25 Mar 2004
Entered Medline: 24 Mar 2004

AB The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib (</=10 microM), which are achievable in patients with minimal toxicity. Moreover, the combination of both drugs results in increased apoptosis in CLL cell lines. These results suggest that imatinib should be useful in improving the therapeutic index of CLB in CLL. The mechanism of action appears to involve imatinib inhibition of c-abl kinase activity with an associated decrease in CLB-induced Rad51 phosphorylation and CLB-induced Rad51 nuclear foci, suggesting that imatinib decreases Rad51-related DNA repair of CLB-induced DNA lesions. Altogether, our results suggest that imatinib is a promising adjuvant therapy to CLB treatment of CLL.

L9 ANSWER 3 OF 3 MEDLINE on STN
ACCESSION NUMBER: 2004008813 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14705499

```
TITLE:              Medication sheets for patients. Oral chemotherapy.
AUTHOR:             Anonymous
SOURCE:             Clinical journal of oncology nursing, (2003 Nov-Dec) Vol.
                    7, No. 6 Suppl, pp. 40-72.
                    Journal code: 9705336. ISSN: 1092-1095.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
                    (PATIENT EDUCATION HANDOUT)
LANGUAGE:           English
FILE SEGMENT:       Nursing Journals
ENTRY MONTH:        200402
ENTRY DATE:         Entered STN: 7 Jan 2004
                    Last Updated on STN: 7 Feb 2004
                    Entered Medline: 6 Feb 2004


=> d his

     (FILE 'HOME' ENTERED AT 09:42:11 ON 24 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 09:42:25 ON 24 JUL 2008
                E "CHLORAMBUCIL"/CN 25
L1            1 S E3
                E "IMATINIB"/CN 25
L2            1 S E3

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 09:43:38 ON 24 JUL
     2008
L3          134 S L1 AND L2
L4           99 S L3 AND COMBINATION
L5           15 S L4 AND CLL
L6            0 S L4 NOT PY>2002
L7            0 S L4 AND PY<2003
L8            1 S L4 AND PY<2004

     FILE 'MEDLINE' ENTERED AT 09:48:35 ON 24 JUL 2008
L9            3 S L1 AND L2

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                     1.04       73.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                     0.00       -1.60

STN INTERNATIONAL LOGOFF AT 09:49:18 ON 24 JUL 2008
```